Radiodione treatment of differentiated thyroid cancer: current status and future prospects

More than 90% of primary thyroid cancers are differentiated papillery or follicular types. The popular treatment of differentiated thyroid carcinoma(DTC) consist of surgery, radioiodine ablation and thyroid stimulating hormone suppressive therapy, which increase clinical benefit rate. During tumor progression, cellular de-differentiation occurs in up to 30% of cases and usually result in the loss of iodine uptake. The current resercbes aiming to improve treatment effect of DTC including clinical application of rhTSH, retinoic acid inducement to re-differentiation and gene therapy on sodium-iodide symporter.